MicroPort CardioFlow Medtech Corporation announced that its new-generation implantable cardioverter defibrillator (ICD), TILEN/EYLEN, has been accepted into the special review procedure for innovative medical devices by the Center for Medical Device Evaluation (CMDE) of the National Medical Products Administration (NMPA). The device is expected to become the first domestically developed MRI-conditional ICD with proprietary intellectual property rights to be approved by the NMPA. The TILEN/EYLEN ICD is part of the National Key R&D Program of the Ministry of Science and Technology and is designed to address technical gaps in the domestic market. Key features include an Auto-MRI function and remote follow-up capabilities using Bluetooth Low Energy technology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Microport Cardioflow Medtech Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260213-12025420), on February 13, 2026, and is solely responsible for the information contained therein.